Austrian Breast & Colorectal Cancer Study Group (Abcsg)

Austrian Breast & Colorectal Cancer Study Group (Abcsg) company information, Employees & Contact Information

Die ABCSG (Austrian Breast & Colorectal Cancer Study Group) ist Österreichs größte und bekannteste akademische Forschungsorganisation, die international erfolgreich klinische Studien zu Brust- und Darmkrebs durchführt. Unsere vorrangigen Ziele sind, die Diagnostik, Therapie und Nachbehandlung österreichweit zu vereinheitlichen und den PatientInnen die bestmögliche, neueste Therapie zukommen zu lassen. Seit 1984 haben rund 29.000 Patientinnen und Patienten weltweit an ABCSG-Studien teilgenommen. The Austrian Breast & Colorectal Cancer Study Group (ABCSG) is Austria’s biggest and best-established academic research organization that conducts internationally respected clinical trials to investigate breast and colon cancer. Our primary objectives are to standardise diagnosis, therapy and post-treatment of breast and colon cancer throughout Austria, and to provide patients with the latest and best possible treatments. More than 29,000 patients worldwide have participated in ABCSG trials since 1984.

Company Details

Employees
34
Founded
-
Address
Vienna, Vienna 1190, At
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Website
abcsg.org
Keywords
Vienna.
HQ
Vienna, Vienna
Looking for a particular Austrian Breast & Colorectal Cancer Study Group (Abcsg) employee's phone or email?

Austrian Breast & Colorectal Cancer Study Group (Abcsg) Questions

News

Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57–18, ABCSG-53, GBG 101) - ScienceDirect.com

Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57–18, ABCSG-53, GBG 101) ScienceDirect.com

Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial - Nature

Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial Nature

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer - BioSpace

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer BioSpace

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) - ASCO Publications

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) ASCO Publications

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer - The New England Journal of Medicine

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer The New England Journal of Medicine

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients - Journal of Experimental & Clinical Cancer Research

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients Journal of Experimental & Clinical Cancer Research

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/A - ASCO Publications

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/A ASCO Publications

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34 - Nature

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34 Nature

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer - The New England Journal of Medicine

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer The New England Journal of Medicine

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial - The Lancet

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial The Lancet

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer - The New England Journal of Medicine

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer The New England Journal of Medicine

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial - Nature

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial Nature

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial - The Lancet

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial The Lancet

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial | British Journal of C - Nature

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial | British Journal of C Nature

Breast-Cancer Adjuvant Therapy with Zoledronic Acid - The New England Journal of Medicine

Breast-Cancer Adjuvant Therapy with Zoledronic Acid The New England Journal of Medicine

Top Austrian Breast & Colorectal Cancer Study Group (Abcsg) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant